Updating results

175 results

Sort: Relevance | Date

Omega-3 fatty acid supplements (KTT4)

KTT4 KTT4

Key therapeutic topic Published January 2015

Three-day courses of antibiotics for uncomplicated urinary tract infection (KTT10)

KTT10 KTT10

Key therapeutic topic Published January 2015 Last updated February 2016

Minocycline (KTT11)

KTT11 Minocycline Options for local implementation Review and, if appropriate, revise

Key therapeutic topic Published January 2015

First-choice antidepressant use in adults with depression or generalised anxiety disorder (KTT8)

KTT8 First-choice antidepressant use in adults with depression or generalised anxiety disorder Options for local implementation

Key therapeutic topic Published January 2015 Last updated February 2016

Laxatives (KTT1)

KTT1 Laxatives Options for local implementation Review and, if appropriate, revise prescribing

Key therapeutic topic Published January 2015

Renin-angiotensin system drugs: dual therapy (KTT2)

KTT2 Renin-angiotensin system drugs: dual therapy Options for local implementation Dual

Key therapeutic topic Published January 2015 Last updated February 2016

Non-steroidal anti-inflammatory drugs (KTT13)

KTT13 Non-steroidal anti-inflammatory drugs Options for local implementation Review

Key therapeutic topic Published January 2015 Last updated February 2018

Biosimilar medicines (KTT15)

KTT15 Biosimilar medicines Options for local implementation Biosimilar medicines have

Key therapeutic topic Published February 2016 Last updated February 2018

Medicines optimisation in chronic pain (KTT21)

KTT21 Medicines optimisation in chronic pain Key points Controlling chronic pain can

Key therapeutic topic Published January 2017 Last updated September 2019

Chemotherapy dose standardisation (KTT22)

KTT22 Chemotherapy dose standardisation Key points Chemotherapy dose standardisation

Key therapeutic topic Published February 2018 Last updated September 2019

Shared decision making (KTT23)

KTT23 Shared decision making Key points In the context of medicines optimisation, shared

Key therapeutic topic Published March 2019 Last updated September 2019

Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide (KTT24)

KTT24 Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide Key points

Key therapeutic topic Published March 2019 Last updated September 2019

Lipid-modifying drugs (KTT3)

KTT3 Lipid-modifying drugs Key points The NICE guideline on cardiovascular disease:

Key therapeutic topic Published January 2015 Last updated September 2019

Asthma: medicines safety priorities (KTT5)

KTT5 Asthma: medicines safety priorities Key points Inhaled corticosteroids (ICS) are

Key therapeutic topic Published January 2015 Last updated September 2019

Hypnotics (KTT6)

KTT6 Hypnotics Key points The risks associated with hypnotics (including melatonin)

Key therapeutic topic Published January 2015 Last updated September 2019

Antipsychotics in people living with dementia (KTT7)

KTT7 Antipsychotics in people living with dementia Key points The risks and limited

Key therapeutic topic Published January 2015 Last updated September 2019

Antimicrobial stewardship: prescribing antibiotics (KTT9)

KTT9 Antimicrobial stewardship: prescribing antibiotics Key points Antimicrobial resistance

Key therapeutic topic Published January 2015 Last updated September 2019

Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)

KTT17 Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI Key points

Key therapeutic topic Published February 2016 Last updated September 2019

Multimorbidity and polypharmacy (KTT18)

KTT18 Multimorbidity and polypharmacy Key points Multimorbidity is associated with

Key therapeutic topic Published January 2017 Last updated September 2019

Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)

KTT19 Psychotropic medicines in people with learning disabilities whose behaviour challenges Key points

Key therapeutic topic Published January 2017 Last updated September 2019

Safer insulin prescribing (KTT20)

KTT20 Safer insulin prescribing Key points Several new insulin products have been launched

Key therapeutic topic Published January 2017 Last updated September 2019

Wound care products (KTT14)

KTT14 Wound care products Key points A large number of wound dressings are available

Key therapeutic topic Published January 2015 Last updated September 2019

Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)

KTT16 Anticoagulants, including direct-acting oral anticoagulants (DOACs) Key points

Key therapeutic topic Published February 2016 Last updated September 2019

Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)

KTT12 Type 2 diabetes mellitus: medicines optimisation priorities Key points The NICE

Key therapeutic topic Published January 2015 Last updated September 2019

Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

Summary of the evidence on doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy in women aged 18 years and older to inform local NHS

Evidence summary Published June 2019

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

Summary of the evidence on fluticasone furoate, umeclidinium and vilanterol (Trelegy) for chronic obstructive pulmonary disease (COPD) to inform local NHS

Evidence summary Published June 2018

Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (ES19)

Summary of the evidence on buprenorphine prolonged-release subcutaneous injection (Buvidal) for opioid dependence to inform local NHS

Evidence summary Published February 2019

Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

Summary of the evidence on bezlotoxumab for preventing the recurrence of Clostridium difficile (C difficile) infection

Evidence summary Published June 2017

Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer

Evidence summary Published July 2017

Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

Summary of the evidence on liraglutide for managing obesity and overweight with risk factors in adults to inform local NHS planning and decision-making

Evidence summary Published June 2017

Asthma: tiotropium (Spiriva Respimat) (ESNM55)

Summary of the evidence on tiotropium (Spiriva Respimat) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Erectile dysfunction: avanafil (ESNM45)

Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published August 2014

Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

Evidence summary Published February 2017

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making

Evidence summary Published March 2017

Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

Summary of the evidence on opicapone for reducing end-of-dose motor fluctuations in Parkinson’s disease to inform local NHS planning and decision-making

Evidence summary Published March 2017

Clostridium difficile infection: fidaxomicin (ESNM1)

Summary of the evidence on fidaxomicin for treating Clostridium difficile (C. diff/C. difficile) infection to inform local NHS planning and decision-making

Evidence summary Published July 2012

Parkinson's disease with motor fluctuations: safinamide (ES6)

Summary of the evidence on safinamide for treating Parkinson’s disease with motor fluctuations to inform local NHS planning and decision-making

Evidence summary Published February 2017

Refractory extrapulmonary sarcoidosis: infliximab (ES4)

Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published January 2017

Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

Summary of the evidence on sucroferric oxyhydroxide for treating hyperphosphataemia in adults with chronic kidney disease (CKD) on dialysis..

Evidence summary Published January 2015

Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

Summary of the evidence on umeclidinium inhaler (Incruse) for chronic obstructive pulmonary disease to inform local NHS planning and decision-making

Evidence summary Published January 2015

Schizophrenia: lurasidone (ESNM48)

Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

Evidence summary Published September 2014

Type 2 diabetes: insulin degludec (ESNM25)

Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published September 2013

Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

Summary of the evidence on aripiprazole prolonged-release suspension for injection for schizophrenia to inform local NHS planning and decision-making

Evidence summary Published March 2014

Gouty arthritis: canakinumab (ESNM23)

Summary of the evidence on canakinumab for treating gouty arthritis (gout) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

Summary of the evidence on the indacaterol/glycopyrronium (Ultibro Breezhaler) for relieving the symptoms of chronic obstructive pulmonary disease (COPD)..

Evidence summary Published February 2014 Last updated March 2014

Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

Summary of the evidence on zonisamide as adjunctive therapy for partial seizures in children and young people (aged 6–17 years) with epilepsy..

Evidence summary Published March 2014

Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

Summary of the evidence on triptorelin (Decapeptyl SR) for treating prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2014

Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

Evidence summary Published September 2014

Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published September 2014

Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

Evidence summary Published March 2015